Copyright © 2012 Saskia F. Heeringa and Clemens D. Cohen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. J. Walport, “Advances in immunology: complement (first of two parts),” The New England Journal of Medicine, vol. 344, no. 14, pp. 1058–1066, 2001. View at Publisher · View at Google Scholar · View at Scopus
2. M. J. Walport, “Advances in immunology: complement (second of two parts),” The New England Journal of Medicine, vol. 344, no. 15, pp. 1140–1144, 2001. View at Publisher · View at Google Scholar · View at Scopus
3. B. Holst, A.-C. Raby, J. E. Hall, and M. O. Labéta, “Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a,” Anaesthesia, vol. 67, no. 1, pp. 60–64, 2012. View at Publisher · View at Google Scholar · View at Scopus
4. P. F. Zipfel and C. Skerka, “Complement regulators and inhibitory proteins,” Nature Reviews Immunology, vol. 9, no. 10, pp. 729–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
5. F. Fakhouri, V. Frémeaux-Bacchi, L. H. Noël, H. T. Cook, and M. C. Pickering, “C3 glomerulopathy: a new classification,” Nature Reviews Nephrology, vol. 6, no. 8, pp. 494–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
6. S. Sethi and F. C. Fervenza, “Membranoproliferative glomerulonephritis—a new look at an old entity,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1119–1131, 2012. View at Publisher · View at Google Scholar · View at Scopus
7. D. P. Gale, E. G. de Jorge, H. T. Cook et al., “Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis,” The Lancet, vol. 376, no. 9743, pp. 794–801, 2010. View at Publisher · View at Google Scholar · View at Scopus
8. J. Caprioli, P. Bettinaglio, P. F. Zipfel et al., “The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 297–307, 2001. View at Scopus
9. E. C. Jackson, A. J. McAdams, C. F. Strife, J. Forristal, T. R. Welch, and C. D. West, “Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation,” American Journal of Kidney Diseases, vol. 9, no. 2, pp. 115–120, 1987. View at Scopus
10. S. Sethi, C. M. Nester, and R. J. H. Smith, “Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion,” Kidney International, vol. 81, no. 5, pp. 434–441, 2012. View at Publisher · View at Google Scholar · View at Scopus
11. S. Sethi, F. C. Fervenza, Y. Zhang et al., “Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 5, pp. 1009–1017, 2011. View at Publisher · View at Google Scholar · View at Scopus
12. A. Servais, L.-H. Noël, L. T. Roumenina et al., “Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies,” Kidney International, vol. 82, no. 4, pp. 454–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
13. J. L. McRae, T. G. Duthy, K. M. Griggs et al., “Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein,” Journal of Immunology, vol. 174, no. 10, pp. 6250–6256, 2005. View at Scopus
14. Y. Athanasiou, K. Voskarides, D. P. Gale et al., “Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1436–1446, 2011. View at Publisher · View at Google Scholar · View at Scopus
15. L. G. Fritsche, N. Lauer, A. Hartmann et al., “An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD),” Human Molecular Genetics, vol. 19, no. 23, pp. 4694–4704, 2010. View at Publisher · View at Google Scholar · View at Scopus
16. A. G. Gharavi, K. Kiryluk, M. Choi et al., “Genome-wide association study identifies susceptibility loci for IgA nephropathy,” Nature Genetics, vol. 43, no. 4, pp. 321–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
17. T. H. Malik, P. J. Lavin, E. G. De Jorge et al., “A hybrid CFHR3-1 gene causes familial C3 glomerulopathy,” Journal of the American Society of Nephrology, vol. 23, no. 7, pp. 1155–1160, 2012. View at Publisher · View at Google Scholar · View at Scopus
18. S. Sethi, F. C. Fervenza, Y. Zhang et al., “C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up,” Kidney International, vol. 82, no. 4, pp. 465–473, 2012. View at Publisher · View at Google Scholar · View at Scopus
19. R. J. H. Smith, C. L. Harris, and M. C. Pickering, “Dense deposit disease,” Molecular Immunology, vol. 48, no. 14, pp. 1604–1610, 2011. View at Publisher · View at Google Scholar · View at Scopus
20. S. Sethi, J. D. Gamez, J. A. Vrana et al., “Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway,” Kidney International, vol. 75, no. 9, pp. 952–960, 2009. View at Publisher · View at Google Scholar · View at Scopus
21. R. E. Spitzer, E. H. Vallota, J. Forristal et al., “Serum C′3 lytic system in patients with glomerulonephritis,” Science, vol. 164, no. 3878, pp. 436–437, 1969. View at Scopus
22. Y. Zhang, N. C. Meyer, K. Wang et al., “Causes of alternative pathway dysregulation in dense deposit disease,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 265–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
23. A. T. Gewurz, S. M. Imherr, S. Strauss, H. Gewurz, and C. Mold, “C3 nephritic factor and hypocomplementaemia in a clinically healthy individual,” Clinical and Experimental Immunology, vol. 54, no. 1, pp. 253–258, 1983. View at Scopus
24. T. H. J. Goodship, I. Y. Pappworth, T. Toth et al., “Factor H autoantibodies in membranoproliferative glomerulonephritis,” Molecular Immunology, vol. 52, no. 3-4, pp. 200–206, 2012. View at Publisher · View at Google Scholar · View at Scopus
25. C. Licht, U. Schlötzer-Schrehardt, M. Kirschfink, P. F. Zipfel, and B. Hoppe, “MPGN II—genetically determined by defective complement regulation?” Pediatric Nephrology, vol. 22, no. 1, pp. 2–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
26. Q. Chen, D. Müller, B. Rudolph et al., “Combined C3b and factor B autoantibodies and MPGN type II,” The New England Journal of Medicine, vol. 365, no. 24, pp. 2340–2342, 2011. View at Scopus
27. T. S. Jokiranta, A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri, “Nephritogenic λ light chain dimer: a unique human miniautoantibody against complement factor H,” Journal of Immunology, vol. 163, no. 8, pp. 4590–4596, 1999. View at Scopus
28. S. Strobel, M. Zimmering, K. Papp, J. Prechl, and M. Józsi, “Anti-factor B autoantibody in dense deposit disease,” Molecular Immunology, vol. 47, no. 7-8, pp. 1476–1483, 2010. View at Publisher · View at Google Scholar · View at Scopus
29. L. Anne-Laure, M. Malina, V. Fremeaux-Bacchi et al., “Eculizumab in severe shiga-toxin—associated HUS,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2561–2563, 2011. View at Publisher · View at Google Scholar · View at Scopus
30. J. Menne, M. Nitschke, R. Stingele et al., “Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study,” British Medical Journal, vol. 345, no. 7869, Article ID e4565, 2012. View at Publisher · View at Google Scholar · View at Scopus
31. E. Daina, M. Noris, and G. Remuzzi, “Eculizumab in a patient with dense-deposit disease,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1161–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
32. S. Radhakrishnan, A. Lunn, M. Kirschfink et al., “Eculizumab and refractory membranoproliferative glomerulonephritis,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1165–1166, 2012. View at Publisher · View at Google Scholar · View at Scopus
33. M. Vivarelli, A. Pasini, and F. Emma, “Eculizumab for the treatment of dense-deposit disease,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1163–1165, 2012. View at Publisher · View at Google Scholar · View at Scopus
34. A. S. Bomback, R. J. Smith, G. R. Barile et al., “Eculizumab for dense deposit disease and C3 glomerulonephritis,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 748–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
35. L. C. Herlitz, A. S. Bomback, G. S. Markowitz et al., “Pathology after eculizumab in dense deposit disease and C3 GN,” Journal of the American Society of Nephrology, vol. 23, no. 7, pp. 1229–1237, 2012. View at Publisher · View at Google Scholar · View at Scopus
36. S. Habbig, M. J. Mihatsch, S. Heinen et al., “C3 deposition glomerulopathy due to a functional factor H defect,” Kidney International, vol. 75, no. 11, pp. 1230–1234, 2009. View at Publisher · View at Google Scholar · View at Scopus
37. C. Licht, A. Weyersberg, S. Heinen et al., “Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15,” American Journal of Kidney Diseases, vol. 45, no. 2, pp. 415–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
38. S. Sethi, F. C. Fervenza, Y. Zhang, and R. J. H. Smith, “Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3,” American Journal of Kidney Diseases, vol. 60, no. 2, pp. 316–321, 2012. View at Publisher · View at Google Scholar · View at Scopus
39. R. C. Wiggins, “The spectrum of podocytopathies: a unifying view of glomerular diseases,” Kidney International, vol. 71, no. 12, pp. 1205–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus